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ABSTRACT
Ulcerative colitis (UC) is a disease of unknown etiology characterized by inflammation of the mucosa and 
occasionally the submucosa of the colon. Conventional drug therapy for UC involves use of aminosalicylates 
(oral, topical, or both) for mild to moderate disease, corticosteroids, azathioprine/6-mercaptopurine, cyclo-
sporine and anti-tumor necrosis factor therapy for a more severe disease. Those patients who do not respond 
to that therapy may require colectomy. In this article the successful use of  hyperbaric oxygen therapy in the 
treatment of ulcerative colitis refractory to conventional therapies is described.
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INTRODUCTION 
Hyperbaric oxygen therapy (HBOT) provides 
100% oxygen under pressure, which increases tis-
sue oxygen levels, relieves hypoxia and alters in-
flammatory pathways. Hyperbaric oxygen therapy 
(HBOT) has been found to be safe and efficacious in 
the treatment of chronic wounds and inflammato-
ry conditions, including inflammatory bowel disease 
(IBD) (1). According to the medical literature the ev-
idence for a positive effect of HBOT is stronger for 
Crohn‘s disease than for ulcerative colitis (2). Dur-
ing treatment, the arterial O
2
 tension often exceeds 
2000 mmHg and levels of 200 to 400 mmHg occur in 
tissues (3). Data from both the acetic acid and trini-
trobenzesulphonic models of colitis in rats indicated 
that the disease severity could be limited with HBOT 
(4).
Case Presentation: 
The patient was a 30-year-old woman diag-
nosed with pan-colonic ulcerative colitis at the age 
of 23. She has had three previous hospitalizations for 
exacerbations of her disease, the most recent of which 
was 2 years prior. At the given moment she had 5 to 
10 bowel movements daily, mixed with blood. She 
complained of general weakness, but did not have el-
evated temperature. Abdominal pain was minimal 
and was more centered in the lower portion. The pa-
tient had been taking 40 to 60 mg/d of prednisone 
over the previous 4 months, with inability to taper; 
she had taken 40 mg/d for the 3 weeks prior to hy-
perbaric therapy, which was continued during treat-
ment. The patient had taken mesalazine (Salofalk - 
3g/d) for several months as well. On physical exam-
ination there was minimal lower abdominal pain. 
From the examinations: Нв 90 g/l, ESR 45 mm/h, 
WBC 11x109. According to the Truelove–Witts score 
(5), as well as according to the Mayo score (6) the coli-
tis was severe. Colonoscopy showed absent vascular 
lines, spontaneous bleeding and presence of ulcers in 
the rectum, the sigmoid, the descending and part of 
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the transverse colon. By the Montreal Classification, 
UC is designated as E3 (7). Multiple biopsies from the 
colon showed marked distortion of glandular archi-
tecture, prominent lamina propria lymphoplasma-
cytic infiltrates and multifocal mucosal neutrophilic 
infiltrates forming numerous crypt abscesses. There 
was extensive mucosal ulceration.
The patient was given 15 courses (2-hour dura-
tion) of HBOT on a 5-day per week. The patient had 
a significant clinical improvement, she had 2 normal 
defecations daily and according to Truelove–Witts 
score the colitis was classified as mild. Colonosco-
py showed mild-to-moderate ulcerative colitis. His-
tologic examination confirmed the clinical improve-
ment. The hemoglobin level was 125 g/l, erythrocyte 
sedimentation rate - 14 mm/h., and white blood cell 
count - 7.5 x109. The dose of corticosteroids was re-
duced by 10 mg every week immediately after the fi-
nal hyperbaric treatment until reaching 20 mg daily 
and after that - by 5 mg every week until the medi-
cine was stopped. In 2 months clinical remission was 
achieved on the basis of the Truelove-Witts score. 
The patient remained on Salofalk – 3g/d. There was 
no recurrence of the disease in the next 4 months. 
DISCUSSION 
This clinical case showed the potential utility of 
HBOT in severe UC, refractory to conventional ther-
apies. There are other reports in the literature con-
cerning the positive effect of HBOT in the complex 
treatment of this disease. The mechanism of this ef-
fect is not known. HBOT has been shown to increase 
the oxygen content of plasma and body tissues and 
may normalize oxygen levels in ischemic tissues (8). 
Immunosuppressive effect due to reduction of B and 
T lymphocytes in experimental models is presumed 
(9). HBOT also lowered pro-inflammatory cytokine 
concentrations and lowered biomarkers of inflam-
mation and oxidative stress (10). Additional studies 
are warranted to investigate both the effects of HBOT 
on biomarkers of oxidative stress and inflammation 
as well as clinical outcomes in individuals with IBD.
CONCLUSIONS 
HBOT has demonstrated efficacy and safety in 
the treatment of ulcerative colitis refractory to con-
ventional therapies.
